logo

For the Inventor, By the Inventor

Kenilworth, NJ, United States of America

Bancha Vibulbhan

This inventor holds 12 USPTO granted patents and 3 EPO patents. Top assignees: Schering Corporation, Merck Sharp + Dohme Corp., Pharmacopeia Inc.. Active years: 1998-2014.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Bancha Vibulbhan. Retrieved from https://idiyas.com/inventor/bancha-vibulbhan

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 12

% Patents Active = 41.7

 

Average Co-Inventor Count = 6.5

ph-index = 5

Forward Citations = 108(Granted Patents)


Company Filing History:

goldMedal11 out of 1,829 
 
Schering Corporation
 patents
silverMedal1 out of 2,405 
 
Merck Sharp + Dohme Corp.
 patents
bronzeMedal1 out of 101 
 
Pharmacopeia Inc.
 patents
where one patent can have more than one assignee

Years Active: 1998-2014

Loading Chart...
Loading Chart...
12 patents (USPTO):Explore Patents
1. 8901139 - Tricyclic indole derivatives and methods of use thereof (2014-12-02),
2. 8143305 - 2,3-substituted indole derivatives for treating viral infections (2012-03-27),
3. 7619094 - Ketoamides with cyclic P4's as inhibitors of NS3 serine protease of hepatitis C virus (2009-11-17),
4. 7449447 - Peptidomimetic NS3-serine protease inhibitors of hepatitis C virus (2008-11-11),
5. 7342016 - Farnesyl protein transferase inhibitors as antitumor agents (2008-03-11),
6. 7173057 - Ketoamides with cyclic P4'S as inhibitors of NS3 protease of hepatitis C virus (2007-02-06),
7. 6846802 - Macrocyclic NS3-serine protease inhibitors of hepatitis C virus comprising N-cyclic P2 moieties (2005-01-25),
8. 6706883 - Process for producing (8-chloro-3,10-dibromo-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-B]pyridin-11-YL)-1-piperdine (2004-03-16),
9. 6528523 - Farnesyl protein transferase inhibitors (2003-03-04),
10. 6426352 - Sulfonamide inhibitors of farnesyl-protein transferase (2002-07-30),
11. 6039683 - Benzo(5,6)cycloheptapyridine cyclic ureas and lactams useful as farnesyl (2000-03-21),
12. 5852034 - Benzo(5,6)cycloheptapyridine cyclic ureas and lactams useful as farnesyl (1998-12-22),

Title: Innovator Spotlight: Bancha Vibulbhan - Pioneering Solutions in Viral Infection Treatment.

Introduction:

Bancha Vibulbhan, a prominent inventor based in Kenilworth, NJ (US), has been at the forefront of developing groundbreaking solutions in the field of viral infection treatment. With an impressive portfolio of 12 patents to his name, Vibulbhan has significantly contributed to advancing healthcare through his innovative research and discoveries.

Latest Patents:

Among his latest patents, Bancha Vibulbhan has introduced Tricyclic Indole Derivatives and 2,3-Substituted Indole Derivatives for treating viral infections. These inventions offer novel compositions and methods for effectively treating or preventing viral infections and related disorders in patients, showcasing his commitment to improving global health outcomes.

Career Highlights:

Throughout his illustrious career, Vibulbhan has held key positions at renowned companies such as Schering Corporation and Pharmacopeia Inc. His expertise and dedication to innovation have been instrumental in shaping the pharmaceutical industry's approach to viral infection treatments, earning him recognition as a leading figure in the field.

Collaborations:

Collaborating with esteemed professionals in the field, Bancha Vibulbhan has worked closely with F George Njoroge and Viyyoor Moopil Girijavallabhan, notable experts known for their contributions to pharmaceutical research. Together, they have synergized their expertise to drive forward pioneering solutions that have the potential to revolutionize viral infection treatment strategies.

Conclusion:

In conclusion, Bancha Vibulbhan's visionary work in the domain of viral infection treatment underscores his unwavering dedication to advancing healthcare through innovation. With a remarkable track record of patents and collaborations with industry leaders, Vibulbhan continues to shape the future of pharmaceuticals, offering hope and healing to patients worldwide.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…